Sun Pharma remains one of Motilal Oswal's top picks in the Indian pharma space on account of its multiple triggers (MK-3222 NDA filing, Ranbaxy synergy benefits, closure of warning letter on Halol), superior execution track record, high RoIC (29%)...
Updated:
Motilal Oswal Securities has Buy call on Sun Pharmaceutical Industries Ltd. with a target price of Rs 925.0. The current market price of Sun Pharmaceutical Industries Ltd. is 849.4. Time period given by analyst is year, when Sun Pharmaceutical Industries Ltd. price can reach defined target. Sun Pharma remains one of Motilal Oswal's top picks in the Indian pharma space on account of its multiple triggers (MK-3222 NDA filing, Ranbaxy synergy benefits, closure of warning letter on Halol), superior execution track record, high RoIC (29%) and cash-rich balance sheet (net cash of $840 million). Motilal Oswal believes its niche appeal will boost near-term profits.